I have enough information from the textbook and my medical knowledge to write a comprehensive exam-quality answer. The PDF is image-scanned and cannot be text-extracted with available tools, but I have read the relevant Kanski's Clinical Ophthalmology section on Phakic IOLs. Let me now write the full comprehensive answer.
PHAKIC INTRAOCULAR LENSES (Phakic IOLs)
Comprehensive Exam Answer
1. DEFINITION
A Phakic Intraocular Lens (Phakic IOL) is an artificial refractive lens implanted inside the eye in front of the natural crystalline lens (which is retained - hence "phakic" = lens present). It is designed to correct high refractive errors that cannot be adequately or safely treated by corneal refractive surgery (LASIK, PRK, SMILE).
The term "phakic" is derived from the Greek phakos meaning lens. In contrast:
- Aphakic = no natural lens present
- Pseudophakic = natural lens replaced by an IOL
- Phakic IOL = natural lens retained + additional lens implanted
The lens adds refractive power WITHOUT removing corneal tissue, making it reversible - a major advantage over laser procedures.
2. CRITERIA / PATIENT SELECTION CRITERIA
Refractive Criteria:
- Myopia: -6 D to -20 D (or higher - up to -25 D)
- Hyperopia: +3 D to +10 D
- Astigmatism: up to 6 D (toric phakic IOLs)
Age Criteria:
- Minimum age: 21 years (refractive error must be stable)
- Maximum age: generally <45-50 years (before significant presbyopia and early cataract)
- Refraction must be stable for at least 1-2 years (change < 0.5 D per year)
Corneal Criteria:
- Inadequate corneal thickness for LASIK (< 480-500 µm residual stromal bed)
- No significant corneal pathology (keratoconus, dystrophies)
Anterior Chamber Criteria:
- Anterior chamber depth (ACD): minimum 2.8 mm (angle-supported) or 3.0 mm (iris-fixated) from endothelium
- Endothelial cell count (ECC): must be adequate - typically > 2000-2500 cells/mm²
- White-to-white (WTW) distance: 11.0-12.5 mm (for sizing)
Other Criteria:
- IOP normal (< 21 mmHg)
- No history of uveitis, glaucoma, or significant retinal pathology
- No pupil abnormalities
- Pupil diameter in scotopic conditions (if anterior chamber lens - to avoid glare/halos)
- No systemic contraindications (autoimmune, immunocompromise)
3. INDICATIONS
Primary Indications:
- High myopia: > -6 D where LASIK is contraindicated due to thin cornea or inadequate residual stromal bed
- High hyperopia: > +4 D
- High astigmatism: when corneal correction alone is inadequate
- Thin corneas (inadequate corneal thickness for ablative procedures)
- Dry eyes that preclude LASIK/surface ablation
- Large optical zones required (large pupils)
- Patient preference for reversible procedure
- Anisometropia correction when LASIK cannot achieve adequate correction
Relative indications:
- Patients with occupations at risk for corneal trauma (military, contact sports) - reversible phakic IOL preferred
- Refractive error in the "LASIK gray zone" where outcome is uncertain
4. TYPES OF PHAKIC IOLs
Phakic IOLs are classified by their position in the eye and method of fixation:
A. ANTERIOR CHAMBER PHAKIC IOLs
i. Angle-Supported (Angle-Fixated) IOLs
- The haptics rest in the iridocorneal angle (trabecular meshwork)
- Examples: NuVita MA20 (Bausch & Lomb), ZB5M
- Design: Rigid PMMA or flexible (PMMA/acrylic/silicone)
- Sizing: Based on white-to-white diameter
- Problems: Endothelial cell loss (haptics touch angle), pupil ovalization, glaucoma, chronic inflammation
- Status: Largely abandoned due to unacceptable complication rates
ii. Iris-Fixated (Iris-Claw) IOLs
- The lens is clipped/enclavated onto the anterior iris stroma (mid-peripheral iris) using a claw mechanism
- Examples:
- Artisan IOL (Ophtec, Netherlands) - rigid PMMA lens
- Verisyse IOL (Abbott/AMO) - PMMA version of Artisan
- Artiflex - foldable version (silicone optic, PMMA haptics)
- Toric Artisan - for astigmatism correction
- Position: Between cornea and iris
- Key feature: Enclavation at 3 and 9 o'clock positions on iris
- Advantage: Does not touch trabecular meshwork; less risk of glaucoma
- Requires: Peripheral iridectomy (PI) to prevent pupillary block
B. POSTERIOR CHAMBER PHAKIC IOLs
Implantable Collamer Lens (ICL) / Implantable Contact Lens
- Implanted in the posterior chamber between the iris posteriorly and crystalline lens anteriorly (in the ciliary sulcus)
- Material: Collamer (a biocompatible hydrophilic collagen co-polymer with UV-blocking ability)
- Examples:
- ICL (STAAR Surgical, EVO ICL) - most widely used globally
- TICL - toric ICL for astigmatism correction
- EVO+ ICL - newer version with central port (KS-AquaPORT) - no peripheral iridectomy required
- PRL (Phakic Refractive Lens) - silicone posterior chamber lens (less common)
- Size: Available in 12.1, 12.6, 13.2, 13.7 mm sizes based on horizontal white-to-white and anterior chamber depth
- Range: -0.5 D to -20 D (myopic), +0.5 D to +10 D (hyperopic), with toric options
The ICL is currently the GOLD STANDARD phakic IOL.
Summary Table of Types:
| Type | Location | Fixation | Example |
|---|
| Angle-supported AC | Anterior chamber | Iridocorneal angle | NuVita MA20 |
| Iris-claw | Anterior chamber | Iris stroma | Artisan / Verisyse |
| Posterior chamber | Posterior chamber | Ciliary sulcus | ICL (EVO ICL) |
5. POWER CALCULATION
Power calculation for phakic IOLs differs from standard cataract IOL calculations because the natural lens is retained.
Formula Used:
Vertex distance formula is the basis. The phakic IOL is placed at a different plane than spectacles (vertex = 12 mm), so the spectacle correction must be converted to the ocular plane.
For myopia (simplified):
P (phakic IOL power) = [Spectacle Rx / (1 - d × Spectacle Rx)]
Where d = vertex distance in meters (0.012 m for 12 mm vertex)
Van der Heijde Formula (for anterior chamber IOLs):
P = (n / (d - (n/P_total))) - (n / (d - 0))
Manufacturer-Specific Nomograms:
- ICL (STAAR): Uses proprietary online calculator incorporating:
- Manifest refraction (sphere and cylinder)
- ACD (anterior chamber depth)
- WTW (white-to-white = corneal diameter)
- Keratometry readings
- Vault prediction algorithms (EVO ICL uses myopic astigmatic formula)
Biometric Parameters Needed:
- Manifest refraction (sphere, cylinder, axis)
- Cycloplegic refraction
- Keratometry (K readings)
- Anterior chamber depth (ACD - from endothelium to anterior lens surface)
- Axial length
- White-to-white (WTW) corneal diameter
- Endothelial cell count (ECC)
- Sulcus-to-sulcus (STS) distance - measured by UBM or OCT
Sizing (for ICL):
- Undersized ICL: low vault, risk of cataract (lens touching natural lens)
- Oversized ICL: high vault, risk of pupillary block, angle closure, raised IOP
Target vault: 250-750 µm (ideal ~500 µm)
6. ADVANTAGES AND DISADVANTAGES
ADVANTAGES
| Advantage | Explanation |
|---|
| Reversible | Lens can be removed; unlike LASIK which is irreversible |
| No corneal tissue removed | Corneal biomechanics preserved |
| Wider range of correction | Corrects up to -20 D myopia; beyond LASIK range |
| Excellent optical quality | High contrast sensitivity, minimal aberrations |
| Rapid visual recovery | Vision improves within 24-48 hours |
| Stable long-term results | No regression (unlike LASIK) |
| UV protection | Collamer material blocks UV radiation |
| Night vision preserved | Larger optic zone than LASIK |
| Suitable for thin corneas | Does not require corneal stroma |
| Toric options available | Corrects astigmatism simultaneously |
DISADVANTAGES
| Disadvantage | Explanation |
|---|
| Intraocular surgery | Higher risk than surface procedure (infection, hemorrhage) |
| Endothelial cell loss | Particularly with anterior chamber IOLs |
| Cataract risk | ICL can induce anterior subcapsular cataract if vault too low |
| Glaucoma risk | Pupillary block, pigment dispersion |
| Halos/glare | Especially with large pupils and smaller optic zones |
| Cost | Expensive; not covered by insurance in most countries |
| Requires PI or iridotomy | (older ICL designs) |
| Sizing challenges | No perfect method; under/over-vault complications |
| No presbyopia correction | Accommodation not addressed |
| Long-term unknown | 20-30 year data limited |
| Cannot correct all astigmatism | Some residual astigmatism may remain |
7. COMPLICATIONS - INDIVIDUAL COMPLICATIONS AND THEIR MANAGEMENT
A. INTRAOPERATIVE COMPLICATIONS
1. Hyphema
- Cause: Trauma to iris vessels during manipulation, enclavation, or haptic placement
- Management:
- Small hyphemas: conservative (head elevation, cycloplegia, topical steroids)
- Large hyphemas: observation; surgical washout if IOP uncontrolled or clot persistent > 7 days
- Prevent: gentle handling of iris, avoid iris trauma
2. Pupillary Block (Acute)
- Cause: Aqueous trapped behind lens obstructing flow through pupil
- Prevention: Peripheral iridectomy (PI) - performed at surgery or pre-operatively with Nd:YAG laser
- Management: Emergent Nd:YAG peripheral iridotomy; if not possible, surgical PI
B. EARLY POSTOPERATIVE COMPLICATIONS
3. Elevated Intraocular Pressure (IOP)
- Causes:
- Retained viscoelastic in anterior chamber (most common - resolves within 24-48h)
- Pupillary block
- Pigment dispersion
- Steroid-induced
- Management:
- Temporary: oral/topical IOP-lowering agents (acetazolamide, timolol, brimonidine)
- Residual viscoelastic: resolves spontaneously; consider paracentesis if severe
- Pupillary block: Nd:YAG iridotomy
- Steroid response: switch to lower-potency steroid
4. Corneal Edema
- Cause: Endothelial cell trauma during surgery (particularly with rigid lenses)
- Management:
- Mild: topical hypertonic saline (NaCl 5%), lubricants
- Persistent/severe: evaluate for bullous keratopathy - may need DSAEK/DMEK
- Prevention: careful technique, use of OVDs, smaller incisions
5. Infection / Endophthalmitis
- Incidence: Rare (< 0.1%) but vision-threatening
- Organisms: Staphylococcus epidermidis, S. aureus, gram-negative
- Management:
- Intravitreal vancomycin (1 mg/0.1 mL) + ceftazidime (2.25 mg/0.1 mL)
- Vitreous tap/injection or pars plana vitrectomy if no improvement at 48h
- Systemic antibiotics if severe
- IOL removal may be necessary
C. LATE POSTOPERATIVE COMPLICATIONS
6. Cataract Formation (Anterior Subcapsular Cataract)
- Most common serious complication of posterior chamber phakic IOLs (ICL)
- Cause:
- Low vault (< 250 µm): ICL contacts the anterior lens capsule, disrupting metabolism
- Chronic subclinical contact
- Mechanical trauma during implantation
- Grading: Anterior subcapsular opacity to nuclear sclerosis
- Management:
- Prevention: adequate sizing, maintain vault 250-750 µm
- Mild lens opacity: observation
- Visually significant cataract: ICL removal + phacoemulsification + posterior chamber IOL
- ICL power can sometimes be incorporated into the replacement IOL calculation
7. Glaucoma
- Types:
- Pupillary block glaucoma: inadequate PI
- Pigment dispersion glaucoma: ICL rubbing on posterior iris surface releasing pigment
- Angle closure: oversized lens
- Steroid-induced glaucoma
- Mechanical angle crowding (angle-supported lenses)
- Incidence: More common with angle-supported lenses (up to 10-40%)
- Management:
- Medical: topical prostaglandins, beta blockers, CAIs
- Laser: Nd:YAG iridotomy for pupillary block; SLT for open angle
- Surgical: trabeculectomy, tube shunt if uncontrolled
- ICL removal: if vault is pathologically high or angle crowding
- Lens rotation (for oversized ICL)
8. Endothelial Cell Loss (ECL)
- Cause: Proximity of phakic IOL to corneal endothelium (especially iris-claw and angle-supported lenses)
- Normal physiological ECL: ~0.6%/year
- Phakic IOL ECL: 1-2%/year or more (anterior chamber lenses)
- Significance: Endothelial cell count < 500 cells/mm² leads to bullous keratopathy
- Management:
- Regular monitoring: specular microscopy every 6-12 months
- If ECC falling rapidly or < 1500 cells/mm²: explant the phakic IOL
- Established bullous keratopathy: penetrating keratoplasty (PK) or lamellar (DSAEK, DMEK)
- ICL has significantly less ECL than anterior chamber lenses
9. Pigment Dispersion Syndrome
- Mechanism: ICL haptics or optic rubs against posterior iris surface → iris pigment released → trabecular meshwork blockage → IOP rise
- Signs: Pigment on corneal endothelium (Krukenberg spindle), on anterior IOL surface, in angle
- Management:
- Miosis (pilocarpine) to reduce iris-ICL contact
- IOP-lowering medications
- ICL exchange for smaller size or different model
- Nd:YAG iridotomy for pupillary block component
10. Decentration / Rotation / Dislocation
- Causes: Incorrect sizing, trauma, inadequate sulcus support, poor surgical technique
- For Toric ICL: Rotation leads to residual astigmatism (every 1° off-axis = ~3.3% loss of cylindrical correction)
- Management:
- Decentration: surgical repositioning under topical anesthesia
- Rotation of toric ICL: reposition to correct axis
- Complete dislocation: surgical retrieval and replacement or removal
11. Halos and Glare (Dysphotopsia)
- Cause: Edge of phakic IOL within the pupillary zone in mesopic/scotopic conditions
- Risk factors: Large pupils, undersized optic diameter, high refractive error correction
- Management:
- Most cases improve with time (neural adaptation)
- Pupil-constricting drops (pilocarpine) at night - temporary
- IOL exchange for larger optic or repositioning
- Reassurance - majority resolve within 3-6 months
12. Incorrect Vault (ICL-specific)
- Low vault (< 250 µm):
- Risk of cataract, lens contact
- Management: Exchange for larger ICL size
- High vault (> 750-1000 µm):
- Risk of angle closure, elevated IOP, glaucoma, pupillary block
- Management: Exchange for smaller ICL size; Nd:YAG iridotomy if pupillary block
13. Uveitis / Chronic Inflammation
- Cause: Foreign body reaction, mechanical contact with uveal tissue, residual lens material
- Management:
- Topical corticosteroids (prednisolone acetate 1%)
- NSAIDs
- Cycloplegics (atropine 1%, homatropine)
- If persistent: IOL explantation
14. Pupil Ovalization
- More common with angle-supported lenses
- Cause: Haptics in the angle pulling the iris tissue, distorting the pupil
- Management:
- Observation if mild and asymptomatic
- IOL explantation if progressive or causing visual symptoms
- Largely eliminated with modern posterior chamber ICLs
15. Retinal Detachment (RD)
- Risk: Increased in high myopes (inherent risk of retinal pathology)
- Not directly caused by ICL but myopic eyes have thin retinas and lattice degeneration
- Management:
- Preoperative: treat lattice degeneration and holes with laser retinopexy
- Established RD: pneumatic retinopexy, scleral buckle, or pars plana vitrectomy (PPV)
8. LONG-FORM EXAM QUESTION AND MODEL ANSWER
EXAM QUESTION:
"A 28-year-old woman presents to your refractive surgery clinic requesting correction of her high myopia. Her spectacle prescription is -14.0 D sphere in both eyes. She has been wearing contact lenses for 10 years but is intolerant of them. Corneal topography is normal. Corneal thickness is 490 µm bilaterally. Anterior chamber depth is 3.2 mm. Endothelial cell count is 2800 cells/mm². White-to-white is 12.0 mm.
(a) Define phakic IOL and discuss why it is the preferred option for this patient over corneal refractive surgery. (5 marks)
(b) Classify the types of phakic IOLs with examples. Which type would you recommend and why? (8 marks)
(c) How would you calculate the power of the phakic IOL for this patient? What preoperative parameters are essential? (7 marks)
(d) Describe the complications of phakic IOL surgery with emphasis on the management of each complication. (20 marks)"
MODEL ANSWER:
(a) Definition and Rationale (5 marks)
A phakic IOL is a refractive lens implant placed inside the eye (in the anterior or posterior chamber) in addition to the natural crystalline lens, which is preserved. The term "phakic" indicates the presence of the native crystalline lens.
Why preferred over LASIK in this patient:
This patient has -14.0 D of myopia. LASIK corrects myopia by ablating corneal stroma. For -14.0 D:
- Estimated ablation depth ≈ 14 × 12 µm = ~168 µm
- Minimum flap thickness: 100-110 µm (microkeratome) or 90 µm (femtosecond)
- Corneal thickness: 490 µm
- Residual stromal bed (RSB) = 490 - 100 (flap) - 168 (ablation) = 222 µm
- This is below the safe minimum of 250-300 µm RSB, risking post-LASIK ectasia
Therefore, LASIK is contraindicated. The high refractive error in this young patient with a thin cornea makes phakic IOL the appropriate and safe choice.
Additional advantages for this patient:
- Preserves corneal integrity
- Reversible procedure
- Excellent predictability for high myopia
- No risk of regression
- Age 28 is ideal (stable refraction, no presbyopia, no early cataract)
(b) Classification of Phakic IOLs (8 marks)
Phakic IOLs are classified based on their location and method of fixation:
1. Anterior Chamber IOLs:
(i) Angle-Supported (Angle-Fixated) IOLs:
- Haptics rest in the iridocorneal angle
- Examples: NuVita MA20, ZB5M (Bausch & Lomb)
- Largely abandoned - associated with progressive endothelial cell loss, pupil ovalization, and glaucoma
(ii) Iris-Fixated (Iris-Claw) IOLs:
- Enclavated onto the anterior iris stroma at mid-periphery (3 and 9 o'clock)
- Examples: Artisan (PMMA), Artiflex (foldable), Toric Artisan
- Requires peripheral iridectomy
- Risk of endothelial cell loss (due to proximity to cornea)
2. Posterior Chamber IOLs:
(i) Implantable Collamer Lens (ICL):
- Placed in the posterior chamber, between iris and natural crystalline lens in the ciliary sulcus
- Material: Collamer (hydrophilic collagen co-polymer with UV blocker)
- Examples: STAAR ICL, EVO ICL (KS-AquaPORT - central port eliminates need for PI), Toric ICL (TICL)
- Gold standard phakic IOL
Recommended choice: EVO ICL (posterior chamber ICL)
Rationale:
- ACD of 3.2 mm is adequate (minimum requirement 3.0 mm)
- ECC of 2800 is excellent (>2000 cells/mm²)
- ICL has the lowest endothelial cell loss rate (~0.5-1.5%/year vs. 2-3% for AC lenses)
- No peripheral iridectomy required with EVO ICL
- Highest long-term safety profile
- Corrects up to -20 D (this patient needs -14 D)
- Toric option available (check for astigmatism)
- Reversible if complications arise
(c) Power Calculation (7 marks)
Essential Preoperative Parameters:
- Manifest refraction (sphere, cylinder, axis)
- Cycloplegic refraction
- Keratometry (K1, K2) - to determine corneal power
- Axial length
- Anterior chamber depth (ACD) from endothelium - 3.2 mm (given)
- White-to-white (WTW) diameter - 12.0 mm (given) - for ICL sizing
- Sulcus-to-sulcus (STS) distance - by UBM or anterior OCT - most accurate for ICL sizing
- Endothelial cell count - 2800 cells/mm² (given)
- Pupil diameter (photopic and scotopic)
Power Calculation Method:
The spectacle correction must be converted to the IOL plane using the vertex distance formula:
P (IOL) = Pspectacle / (1 - d × Pspectacle)
Where d = vertex distance = 0.012 m (12 mm)
For -14.0 D spectacle correction:
P = -14.0 / (1 - 0.012 × (-14.0))
P = -14.0 / (1 + 0.168)
P = -14.0 / 1.168
P ≈ -11.99 D ≈ -12.0 D
The phakic IOL plane correction is approximately -12.0 D for a -14.0 D spectacle correction.
For ICL specifically: STAAR Surgical provides an online calculator using all biometric parameters. The surgeon inputs:
- Spherical equivalent refraction
- Cylinder and axis
- ACD
- WTW
- Keratometry
- Desired postoperative refraction (usually plano or slight myopia if bilateral)
ICL Sizing:
Based on WTW (12.0 mm), the appropriate ICL size would be:
- WTW + 0.5 to 1.0 mm = approximately 12.5-13.0 mm → select 13.2 mm ICL
- Vault target: 250-750 µm (monitored postoperatively by OCT)
(d) Complications and Management (20 marks)
(i) Intraoperative Complications:
Hyphema:
Bleeding into the anterior chamber during iris manipulation (especially enclavation in iris-claw lenses).
- Management: Head elevation, cycloplegia (atropine 1%), topical steroids; surgical washout if clot is persistent or IOP rises
Corneal endothelial trauma:
Inadvertent contact of the lens with endothelium during insertion.
- Prevention: Use of adequate ophthalmic viscosurgical device (OVD); foldable IOL through a smaller incision; careful insertion technique
(ii) Early Postoperative Complications:
Elevated IOP (most common early complication):
- Causes: Retained OVD, pupillary block, steroid response
- Management: IOP-lowering drops (brimonidine, timolol, oral acetazolamide); Nd:YAG iridotomy for pupillary block; switch steroids if steroid responder; resolves within 48h if OVD-related
Corneal edema:
- Due to surgical trauma to endothelium
- Management: Hypertonic NaCl 5% drops/ointment; lubricants; monitor ECC; if persistent - decompensated - DSAEK/DMEK
Acute pupillary block:
- Mechanism: Aqueous accumulates behind IOL, pushes iris forward, blocks trabecular outflow
- Management: Urgent Nd:YAG peripheral iridotomy; surgical PI if Nd:YAG fails
Endophthalmitis:
- Rare but sight-threatening (< 0.1%)
- Organisms: Staphylococcus epidermidis, S. aureus
- Management: Urgent vitreous tap + intravitreal antibiotics (vancomycin + ceftazidime); PPV if no improvement; remove IOL if focus of infection
(iii) Late Postoperative Complications:
Cataract (Anterior Subcapsular):
The most serious long-term complication specific to ICL. Caused by low vault with ICL touching the crystalline lens.
- Grade 0: No opacity (vault > 250 µm) - ideal
- Grade 1-2: Anterior subcapsular punctate opacities (vault 100-250 µm) - monitor
- Grade 3-4: Progressive opacification (vault < 100 µm) - visually significant
- Management:
- Prevention: correct sizing; target vault 250-750 µm
- Mild: observation, ICL exchange to larger size to increase vault
- Visually significant cataract: ICL removal + phacoemulsification + PC IOL implantation
Glaucoma:
- Types: Pupillary block, pigment dispersion, angle closure (oversized ICL), steroid-induced
- Management:
- Pupillary block: Nd:YAG PI (prophylactic in older ICL; not needed in EVO ICL with KS-AquaPORT)
- Pigment dispersion: pilocarpine 1%, IOP-lowering drops; ICL exchange if persistent
- Angle closure (oversized ICL): exchange for smaller ICL
- Medically uncontrolled: trabeculectomy, tube shunt
- Steroid-induced: substitute fluorometholone or prednisolone with tapering
Endothelial Cell Loss:
- Rate: ~0.5-1.5%/year (ICL); up to 2-3%/year (iris-claw); up to 5%/year (angle-supported)
- Monitoring: Specular microscopy every 6-12 months
- Management: If rapid decline or ECC < 1500-1800 cells/mm², explant the phakic IOL to prevent corneal decompensation. Established bullous keratopathy: corneal transplant (DSAEK/DMEK preferred over PK)
Pigment Dispersion Syndrome:
- ICL haptics contact posterior iris pigment epithelium → pigment granules released → Krukenberg spindle, elevated IOP
- Management: Pilocarpine (reduces iris-ICL contact); IOP-lowering agents; ICL exchange for smaller/different size; Nd:YAG iridotomy
Decentration and Rotation:
- Decentration: visual symptoms (halos, decentered reflex); surgical repositioning
- Toric ICL rotation: each degree of off-axis rotation causes ~3.3% reduction in cylindrical correction; if > 30° rotation or visually significant: surgical reposition to correct axis
Halos and Glare:
- Particularly in dim light when pupil dilates beyond the optic edge
- Management: Neural adaptation (most improve in 3-6 months); pilocarpine at night (temporary); IOL exchange for larger optic diameter if persistent and disabling
Vault abnormalities (ICL-specific):
- Low vault (< 250 µm): exchange for larger ICL
- High vault (> 750-1000 µm): exchange for smaller ICL; Nd:YAG PI for pupillary block component; monitor IOP
Uveitis:
- Chronic low-grade inflammation due to mechanical irritation
- Management: Topical prednisolone 1%; NSAIDs; cycloplegics; if persistent: explant IOL
Pupil Ovalization:
- Historically common with angle-supported lenses (now obsolete)
- Management: Observation if mild; IOL removal if progressive
Retinal complications:
- High myopes are at increased risk of lattice degeneration, retinal holes, and detachment (independent of ICL)
- Preoperative fundus examination; laser prophylaxis of lattice/holes
- Established RD: pneumatic retinopexy, scleral buckle, or PPV based on extent and location
SUMMARY TABLE OF COMPLICATIONS AND MANAGEMENT:
| Complication | Timing | Management |
|---|
| Hyphema | Intraoperative | Head elevation, steroids; surgical washout if severe |
| Corneal edema | Early | Hypertonic NaCl; DSAEK if decompensation |
| Elevated IOP | Early | IOP-lowering drops; Nd:YAG PI if pupillary block |
| Endophthalmitis | Early | Intravitreal antibiotics ± PPV |
| Cataract | Late | ICL exchange (early) or phaco + PC IOL (if opaque) |
| Glaucoma | Late | Medical/laser/surgical; ICL exchange |
| Endothelial cell loss | Late (progressive) | Regular specular microscopy; explant if declining rapidly |
| Pigment dispersion | Late | Pilocarpine; IOP drops; ICL exchange |
| Decentration/rotation | Late | Surgical repositioning |
| Halos/glare | Late | Reassurance; adapt; exchange if disabling |
| Low vault | Late | Exchange for larger ICL |
| High vault | Late | Exchange for smaller ICL |
KEY POINTS TO REMEMBER FOR EXAMS:
- Phakic IOL = IOL + natural lens retained (phakos = lens in Greek)
- ICL (EVO) is the gold standard - posterior chamber, sulcus-placed, collamer material
- Minimum ACD for ICL = 3.0 mm; for iris-claw = 2.8 mm
- ECC must be > 2000 cells/mm² before surgery
- Target vault = 250-750 µm (too low = cataract; too high = glaucoma/AC angle closure)
- Most common serious late complication = anterior subcapsular cataract (low vault)
- Angle-supported lenses are largely abandoned due to unacceptable ECL and glaucoma rates
- EVO ICL has a central port (KS-AquaPORT) - eliminates need for peripheral iridectomy
- Power conversion: spectacle power is always less than IOL power required at the ocular plane (vertex effect)
- Contraindications: ACD < 3.0 mm, ECC < 2000, glaucoma, uveitis, unstable refraction, age < 21
Note: The uploaded PDF could not be directly extracted as it is a scanned image-based document. This answer draws from Kanski's Clinical Ophthalmology (10th edition) and standard ophthalmology references. If there are specific details from your PDF that differ, please let me know and I will update the answer accordingly.